Cargando…

Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine

RADA16 is a synthetic peptide that exists as a viscous solution in an acidic formulation. In an acidic aqueous environment, the peptides spontaneously self-assemble into β-sheet nanofibers. Upon exposure and buffering of RADA16 solution to the physiological pH of biological fluids such as blood, int...

Descripción completa

Detalles Bibliográficos
Autores principales: Sankar, Sharanya, O’Neill, Kate, Bagot D’Arc, Maurice, Rebeca, Florian, Buffier, Marie, Aleksi, Elton, Fan, Melanie, Matsuda, Noriaki, Gil, Eun Seok, Spirio, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216384/
https://www.ncbi.nlm.nih.gov/pubmed/34164387
http://dx.doi.org/10.3389/fbioe.2021.679525
_version_ 1783710407599325184
author Sankar, Sharanya
O’Neill, Kate
Bagot D’Arc, Maurice
Rebeca, Florian
Buffier, Marie
Aleksi, Elton
Fan, Melanie
Matsuda, Noriaki
Gil, Eun Seok
Spirio, Lisa
author_facet Sankar, Sharanya
O’Neill, Kate
Bagot D’Arc, Maurice
Rebeca, Florian
Buffier, Marie
Aleksi, Elton
Fan, Melanie
Matsuda, Noriaki
Gil, Eun Seok
Spirio, Lisa
author_sort Sankar, Sharanya
collection PubMed
description RADA16 is a synthetic peptide that exists as a viscous solution in an acidic formulation. In an acidic aqueous environment, the peptides spontaneously self-assemble into β-sheet nanofibers. Upon exposure and buffering of RADA16 solution to the physiological pH of biological fluids such as blood, interstitial fluid and lymph, the nanofibers begin physically crosslinking within seconds into a stable interwoven transparent hydrogel 3-D matrix. The RADA16 nanofiber hydrogel structure closely resembles the 3-dimensional architecture of native extracellular matrices. These properties make RADA16 formulations ideal topical hemostatic agents for controlling bleeding during surgery and to prevent post-operative rebleeding. A commercial RADA16 formulation is currently used for hemostasis in cardiovascular, gastrointestinal, and otorhinolaryngological surgical procedures, and studies are underway to investigate its use in wound healing and adhesion reduction. Straightforward application of viscous RADA16 into areas that are not easily accessible circumvents technical challenges in difficult-to-reach bleeding sites. The transparent hydrogel allows clear visualization of the surgical field and facilitates suture line assessment and revision. The shear-thinning and thixotropic properties of RADA16 allow its easy application through a narrow nozzle such as an endoscopic catheter. RADA16 hydrogels can fill tissue voids and do not swell so can be safely used in close proximity to pressure-sensitive tissues and in enclosed non-expandable regions. By definition, the synthetic peptide avoids potential microbiological contamination and immune responses that may occur with animal-, plant-, or mineral-derived topical hemostats. In vitro experiments, animal studies, and recent clinical experiences suggest that RADA16 nanofibrous hydrogels can act as surrogate extracellular matrices that support cellular behavior and interactions essential for wound healing and for tissue regenerative applications. In the future, the unique nature of RADA16 may also allow us to use it as a depot for precisely regulated drug and biopharmaceutical delivery.
format Online
Article
Text
id pubmed-8216384
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82163842021-06-22 Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine Sankar, Sharanya O’Neill, Kate Bagot D’Arc, Maurice Rebeca, Florian Buffier, Marie Aleksi, Elton Fan, Melanie Matsuda, Noriaki Gil, Eun Seok Spirio, Lisa Front Bioeng Biotechnol Bioengineering and Biotechnology RADA16 is a synthetic peptide that exists as a viscous solution in an acidic formulation. In an acidic aqueous environment, the peptides spontaneously self-assemble into β-sheet nanofibers. Upon exposure and buffering of RADA16 solution to the physiological pH of biological fluids such as blood, interstitial fluid and lymph, the nanofibers begin physically crosslinking within seconds into a stable interwoven transparent hydrogel 3-D matrix. The RADA16 nanofiber hydrogel structure closely resembles the 3-dimensional architecture of native extracellular matrices. These properties make RADA16 formulations ideal topical hemostatic agents for controlling bleeding during surgery and to prevent post-operative rebleeding. A commercial RADA16 formulation is currently used for hemostasis in cardiovascular, gastrointestinal, and otorhinolaryngological surgical procedures, and studies are underway to investigate its use in wound healing and adhesion reduction. Straightforward application of viscous RADA16 into areas that are not easily accessible circumvents technical challenges in difficult-to-reach bleeding sites. The transparent hydrogel allows clear visualization of the surgical field and facilitates suture line assessment and revision. The shear-thinning and thixotropic properties of RADA16 allow its easy application through a narrow nozzle such as an endoscopic catheter. RADA16 hydrogels can fill tissue voids and do not swell so can be safely used in close proximity to pressure-sensitive tissues and in enclosed non-expandable regions. By definition, the synthetic peptide avoids potential microbiological contamination and immune responses that may occur with animal-, plant-, or mineral-derived topical hemostats. In vitro experiments, animal studies, and recent clinical experiences suggest that RADA16 nanofibrous hydrogels can act as surrogate extracellular matrices that support cellular behavior and interactions essential for wound healing and for tissue regenerative applications. In the future, the unique nature of RADA16 may also allow us to use it as a depot for precisely regulated drug and biopharmaceutical delivery. Frontiers Media S.A. 2021-06-02 /pmc/articles/PMC8216384/ /pubmed/34164387 http://dx.doi.org/10.3389/fbioe.2021.679525 Text en Copyright © 2021 Sankar, O’Neill, Bagot D’Arc, Rebeca, Buffier, Aleksi, Fan, Matsuda, Gil and Spirio. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Sankar, Sharanya
O’Neill, Kate
Bagot D’Arc, Maurice
Rebeca, Florian
Buffier, Marie
Aleksi, Elton
Fan, Melanie
Matsuda, Noriaki
Gil, Eun Seok
Spirio, Lisa
Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine
title Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine
title_full Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine
title_fullStr Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine
title_full_unstemmed Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine
title_short Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine
title_sort clinical use of the self-assembling peptide rada16: a review of current and future trends in biomedicine
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216384/
https://www.ncbi.nlm.nih.gov/pubmed/34164387
http://dx.doi.org/10.3389/fbioe.2021.679525
work_keys_str_mv AT sankarsharanya clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine
AT oneillkate clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine
AT bagotdarcmaurice clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine
AT rebecaflorian clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine
AT buffiermarie clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine
AT aleksielton clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine
AT fanmelanie clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine
AT matsudanoriaki clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine
AT gileunseok clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine
AT spiriolisa clinicaluseoftheselfassemblingpeptiderada16areviewofcurrentandfuturetrendsinbiomedicine